Charted
Wednesday, Nov. 18, 2026The business of health, by the numbers
Live trackersDeal tracker $7.07B raisedFDA clearances 293 510(k)s in OctoberForm D raises $839M in 30 daysNew trials 266 Phase 2/3 in 30 days
Biotech·Marrow Therapeutics

Marrow Therapeutics launches with $173M to send genetic medicines straight to bone marrow

OrbiMed led a $120 million Series B on top of a $53 million Series A co-led by Scion Life Sciences and venBio. Marrow's lead drug, for sickle cell disease and beta thalassemia, is in IND-enabling studies.

From a company announcement published Nov. 17, 2026
A peripheral blood smear from a patient with sickle cell anemia, seen under a microscope, with sickle-shaped red blood cells among round ones.
A peripheral blood smear from a patient with sickle cell anemia, seen under a microscope, with sickle-shaped red blood cells among round ones. File photo.Ed Uthman / Wikimedia Commons (CC BY 2.0)
Amount
$173M
Type
Series B
Company
Marrow Therapeutics
Led by
OrbiMed, Scion Life Sciences, venBio
Sector
Biotech
Announced
Nov. 17, 2026

Marrow Therapeutics launched Nov. 17 with $173 million and a plan to deliver genetic medicines to bone marrow cells inside the body, an approach known as in vivo. The Watertown, Mass., company is starting with sickle cell disease and beta thalassemia.

The money came in two rounds. Scion Life Sciences, which founded Marrow, and venBio co-led a $53 million Series A. OrbiMed then led a $120 million Series B, joined by every Series A investor and new funds including RTW Investments, Surveyor Capital (a Citadel company), Opaleye, NEXTBio Capital, Affinity Advisors, KKR, Spruce Street Capital and Columbia Threadneedle Investments. Marrow did not disclose a valuation.

Why it matters: Marrow is betting that targeted delivery can address what it calls the safety, manufacturing and access limits of earlier genetic medicine approaches for blood disorders. Its lead program is still in preclinical, IND-enabling studies, so investors committed $173 million well before any human data.

How the approach works

Marrow's platform, which it calls Transferrin Antibody Bioconjugate, or TAB, uses engineered antibodies that bind the transferrin receptor, TfR1, on bone marrow cells and carry a therapeutic payload into them in the body, according to the company. Marrow said its team has experience engaging that receptor while avoiding off-target effects, in particular the anemia risk that it said limits other TfR1-targeted approaches.

The lead candidate, MAR-101, is in IND-enabling studies, the preclinical work needed before the FDA can allow human trials. It is meant to address both sickle cell disease and beta thalassemia by lowering BCL11a and switching fetal hemoglobin production back on, the company said. Marrow said it has other programs in development across blood and bone marrow diseases but did not name them.

"What is particularly compelling is their 'pipeline in a product' strategy," said Mona Ashiya, a general partner at OrbiMed, referring to MAR-101's use across two diseases.

The team

Romesh Subramanian is president and chief executive. Tim Weeden is chief scientific officer, John Najim is chief operating officer and chief technology officer, and Gavriel Mullokandov is founder and vice president of corporate development. Ashiya said members of the team have taken earlier TfR1-based platforms into human testing before.

Art Levin, the founding chief scientific officer of Avidity Biosciences, joined the board. Stuart Orkin, a Harvard Medical School pediatrics professor and Howard Hughes Medical Institute investigator at Boston Children's Hospital, joined the scientific advisory board.

What comes next

The company did not give a date for filing an investigational new drug application. Aaron Kantoff, co-founder and managing partner at Scion Life Sciences, gave the clearest timeline. "We are truly excited to see Marrow advance its programs into the clinic in the coming year," he said.

Sara Montes de Oca is the Editor in Chief of Charted. She previously worked as a correspondent and producer in Washington, D.C., covering business, finance, and politics. Drafted with automated tools from the sources listed with this story and checked against them before publishing. How we report.

More Biotech

More
Newsletter

Charted Daily

The day's deals, FDA decisions and policy moves, by the numbers. Free. Sign up now to get the first edition.

No spam. Unsubscribe any time.